MB-HSPG@EC2607A

Hansoh Pharmaceutical's Aumolertinib Receives EU Approval for Lung Cancer

Hanson Pharma's Amivantamab Pill Approved for EU Market

Nomura Raises Hansoh Pharmaceutical's 2025 Fiscal Year Revenue and Profit Forecast

Hansoh Pharmaceutical Successfully Issued Zero-Coupon Convertible Bonds Worth HK$4.68 Billion

Hanson Pharmaceutical Plans to Raise HK$4.68 Billion Through Convertible Bonds

Hansoh Pharmaceutical's Aumolert® Approved for New Indication

Hanson Pharma Grants Glenmark Exclusive License for Aumolertinib, Expands International Market Layout

Hanson Pharma Signs License Agreement with Jiangsu Hengrui for SHR6508

Glenmark Pharmaceuticals Ltd Secures Exclusive Rights to Aumolertinib from Hansoh Pharmaceutical

Hansoh Pharmaceutical's Wholly-owned Subsidiary Enters into Exclusive Licensing, Collaboration and Distribution Agreement for Amivantamab with Glenmark

UBS Analyst Maintains Buy Rating on Hansoh Pharmaceutical

Hanson Pharmaceutical Group Reports Strong Phase II Clinical Trial Results for RET Inhibitor Resencatinib

Hanson Pharmaceutical's risvutatug rezetecan shows promising results in Phase 1 trial for NSCLC

Hanson Pharma’s Multiple Drugs Included in the New National Health Insurance Directory

UBS Analyst Maintains Buy Rating on Hengshen Pharmaceutical, with a Target Price of HKD 48.20

Hanson Pharmaceutical Reports Phase 2 Trial Results for HS-20089 for Platinum-Resistant Ovarian Cancer

Huatai Securities Maintains Buy Rating on Hansoh Pharmaceutical Group

Hanson Pharma Signs HS-20110 Licensing Agreement with Roche

Zhong Huijuan Leads Hansoh Pharmaceutical's Innovation Transformation to Become China's New Female Richest

Zhong Huijuan Becomes China's New Female Rich List Top

STARCOIN GROUP

DAISHOMICROLINE

IDT INT'L

GUANZE MEDICAL

BOER POWER

KNOWLEDGE ATLAS

CHINA INFO TECH

QINGHUA HOLD

SUPER STRONG

HAIZHI TECH GP

03692

Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, received approval in the European Union as a monotherapy for treating advanced non-small cell lung cancer (NSCLC). This includes first-line treatment for adult patients with specific EGFR mutations and treatment for those with EGFR T790M mutation-positive NSCLC. The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.

marketscreener

HANSOH PHARMA

Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy

Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY

Reuters

Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy

Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib

Tip Ranks

Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral

Nomura has raised the target price for HANSOH PHARMA to RMB 37.87, expecting a 10% growth in both revenue and profit for the fiscal year 2026. Revenue in the second half of 2025 is expected to grow by 27% to RMB 7.3 billion, with drug sales increasing by 17% to RMB 6.6 billion and collaboration revenue at RMB 743 million. The gross margin is expected to be 91.6%, and the operating profit margin is 26.9%. It is anticipated that the net profit attributable to shareholders in the second half of 2025 will be RMB 2.1 billion, an increase of 29.4%. At the same time, the revenue and profit forecasts for the fiscal year 2025 have been raised by 1% and 4.7%, respectively, maintaining a "Neutral" rating

AASTOCKS

Nomura raises HANSOH PHARMA's target price to 37.87 yuan, upgrading revenue and earnings estimates

159316

512290

159570

513700

520500

520880

159992

513120

159506

520690

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

SKB BIO-B

ChinaAMC SSE STAR Biology and Medicine ETF

KELUN PHARMA

HENLIUS

WEIGAO GROUP

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

HYGEIA HEALTH

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

WuXi AppTec

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

WUXI XDC

Ping An CSI Medicine and Medical Device Innovation ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI APPTEC

Bosera Hang Seng SCHK Innovative Drug Select ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

HANSOH PHARMA - B announced that the company has initiated a Phase I clinical trial for its self-developed candidate drug HX111 (a candidate drug targeting OX40 antibody conjugate) for relapsed refractory lymphoma and solid tumors, successfully completing the first patient enrollment and dosing recently

HANSOH PHARMA's candidate drug HX111 has completed the first patient dosing

Hansoh Pharmaceutical Sells HK$4.68 Billion Convertible Bonds

Hansoh Pharmaceutical Sells HK$4.68 Billion Convertible Bonds

Hansoh Pharmaceutical Group Co. Ltd. has announced the successful placement of HK$4.68 billion zero-coupon convertible bonds maturing in 2033. The issuance was completed on February 3, 2026, after all conditions were met. The convertible bonds are set to be listed on the Vienna MTF.

Hansoh Pharmaceutical Group platziert HK$4,68 Milliarden Zero-Coupon-Wandelanleihen

00100

02259

02513

02628

09626

06181

01171

01880

09927

MINIMAX-WP(00100) rose 26.48%, with a trading turnover 1.6 Billion HKD, and a year-to-date rose 195.9%. ZIJIN GOLD INTL(02259) rose 11.59%, with a trading turnover 3.1 Billion HKD, and a year-to-date rose 59.6%. HANSOH PHARMA(03692) fell 4.37%, with a trading turnover 420.6 Million HKD, and a year-to-date rose 6.7%. LAOPU GOLD(06181) fell 3.24%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 33%.

- The Hang Seng Index rose by 1.35%, with a year-to-date increase of 5.8%, while the Hang Seng Tech Index increased by 0.5%, totaling a 4.3% rise this year.  
- MINIMAX-WP (00100) surged by 26.48% with a turnover of HK$ 1.61 billion, marking a significant annual increase of 195.9%.  
- In contrast, Hansoh Pharmaceutical (03692) fell by 4.37% with a turnover of HK$ 420 million, showing a modest year-to-date increase of 6.7%.

Top Gainers & Losers

MINIMAX-WP

ZIJIN GOLD INTL

CHINA LIFE

BILIBILI-W

LAOPU GOLD

YANKUANG ENERGY

CTG DUTY-FREE

SERES

Top 5 HK Stock Gainers/Losers (>100B) (1.27)

Hansoh Pharmaceutical Group Company Limited plans to raise HK$4.68 billion through the issuance of zero-coupon convertible bonds due 2033. The bonds, convertible into approximately 81.5 million shares at an initial price of HK$57.39 per share, will be offered to professional investors in Hong Kong and outside the U.S. The net proceeds will be used as specified by the company, but completion is subject to certain conditions. The latest analyst rating for the stock is a Buy with a price target of HK$48.20.

Hansoh Pharmaceutical to Raise HK$4.68 Billion via Zero-Coupon Convertible Bonds

MB-HSPG@EC2607A(23333.HK)

Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy

Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy

Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral

Nomura raises HANSOH PHARMA's target price to 37.87 yuan, upgrading revenue and earnings estimates